查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827959

避孕药市场按类型、剂型、作用机制、材料类型、使用期限、使用频率、销售管道、应用和最终用户划分 - 2025-2032 年全球预测

Contraceptive Market by Type, Formulation, Mode Of Action, Material Type, Duration, Usage Frequency, Sales Channel, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年避孕药具市场将成长 690.2 亿美元，复合年增长率为 7.60%。

主要市场统计数据
基准年2024年 384亿美元
预计2025年 411.3亿美元
预测年份：2032年 690.2亿美元
复合年增长率（%） 7.60%

现代避孕领域的策略方向，强调创新、可近性、监管细节和以使用者为中心的优先事项

避孕领域正处于曲折点，临床创新、不断变化的消费者期望以及不断变化的政策环境正在重塑产品开发和获取途径。生物医学技术和製剂科学的进步正在扩大终端用户的选择范围，而数位健康平台和远端医疗正在改变避孕药的研发、剂量和取得途径。同时，围绕生殖自主权和整体性的社会对话正在影响需求模式以及产品面临的监管审查。这些动态要求整个价值链上的相关人员不仅要考虑功效和安全性，还要考虑使用者体验、可接受性和获取的公平性。

从传统产品系列转向面向未来的产品组合，需要深入了解临床差异化和最终用户细分。医疗系统和支付方优先考虑长期疗效和经济高效的照护途径，这会影响筹资策略和剂量决策。同时，製造商和创新者必须加快下一代产品的开发，同时应对复杂的供应链、法规遵循和永续性的考量。这些因素的结合，既为定向创新创造了重大机会，也为那些适应缓慢的组织带来了严重的营运风险。因此，本引言建构了分析其余部分所反映的更广泛的模式，并为将科学进步与现实世界的可及性和商业性可行性相结合的实用建议奠定了基础。

技术、分销、材料和监管实践方面的重大系统性变化正在重新定义避孕选择和交付模式

过去十年，在科技、消费行为和医疗保健系统优先事项的共同推动下，多项变革性变革重新定义了避孕领域。长效、可逆的避孕方法在临床指南和实践中变得越来越重要，製造商也强调了其耐用性、易于插入和最小副作用。同时，荷尔蒙和非荷尔蒙製剂的进步拓展了治疗方法选择，包括植入、注射、口服系统、经皮吸收贴片和屏障疗法，从而实现了更个人化的护理途径。

数位化和分销创新正在加速变革，减少处方获取和依从性支持方面的摩擦。远端医疗咨询与电子商务和线上药局履约结合，正在改变传统临床管道和消费者直销管道之间的平衡。同时，材料科学的进步，例如传统乳胶产品的替代品，正在为解决过敏问题和提升用户舒适度创造机会。监管环境正在适应这些创新，但也带来了临床终点、上市后监管和跨境分销的复杂性。这些转变并非渐进式的；它们正在改变产品的开发、行销和交付方式，迫使相关人员在日益互联的生态系统中重新思考临床参与、病患教育和供应链韧性。

评估主要市场的关税如何重塑整个避孕供应链的采购、材料选择、库存规划和获取动态

2025年主要经济体实施的关税措施立即对全球避孕用品及其组成材料的供应链产生了波动。从受影响国家和地区采购原材料和零件的製造商面临更高的到岸成本，这促使他们迅速审查筹资策略和供应商多元化。在许多情况下，契约製造和成品製造商开始评估近​​岸外包方案、双重采购安排和库存管理方法，以减轻影响，从而影响了医院、药房和电商经销商的前置作业时间和库存模式。

除了采购之外，关税相关的成本压力也影响了产品配方和材料选择的策略决策。例如，供应链敏感性导致在阻隔产品中使用非乳胶替代品，例如腈纶、聚异戊二烯和聚氨酯。监管合规成本和海关延误也为时间敏感的产品发布和事后紧急避孕药带来了阻​​力，因为这些措施需要快速的通路。临床医生和卫生系统因采购时间延误而负担沉重，付款人和采购团体开始仔细审查其对总成本的影响，包括对患者取得药品的下游影响。因此，供应链透明度、合约弹性和策略采购成为避孕领域公司的核心竞争力。

将产品类型、配方、作用机制、材料和最终用户概况与可操作的开发和商业策略联繫起来的细粒度细分洞察

细分市场差异化为确定产品开发和商业策略的优先顺序提供了一个实用框架。依类型，事后紧急避孕药分为子宫内避孕器和避孕药；荷尔蒙避孕法分为植入式避孕法、注射式避孕法、口服经皮和透皮贴片；非荷尔蒙避孕法分为屏障避孕法；草药避孕法分为传统和自然避孕法，例如阿育吠陀和同类疗法；永久性避孕方法则包括输卵管结扎术和输精管结扎术。这些差异凸显了不同的临床途径：长效和永久性避孕方法往往需要专科护理和医疗保健系统采购，而避孕药、贴片和屏障避孕法通常需要更广泛的基层医疗和零售管道。

就剂型而言，贴片、药丸和环的依从性和可接受性各有不同。作用机制的分类—预防着床、杀精或抑制排卵—直接影响临床结果和病患教育重点，并影响标籤检视和安全监测。材料分为乳胶基和非乳胶基，后者又细分为腈纶、聚异戊二烯和聚氨酯，每种材料在成本、质地和致敏性方面各有优劣。

依使用时间长度和使用频率细分，可区分长期使用和短期使用、按需使用和常规使用，并突显参与度和依从性的介入途径。销售管道区分线下门市（例如医院药局和零售药局）和线上通路（例如电商平台和线上药局），并突显购买行为的变化。应用区分一般用途和性交后使用，并突显紧急程度和配送要求的差异。终端使用者细分可识别女性和男性群体，进一步将女性细分为青少年、成人和停经后群体，从而影响临床指导、行销基调和包装。这些细分视角提供了一致的地图，用于根据特定的临床和消费者需求调整产品功能、监管策略和产品发布。

区域战略要务，解释监管多样性、文化规范、製造地和获取模式如何影响全球市场上避孕药具的部署

区域动态对产品采用、监管途径和分销模式有重大影响。在美洲，都市区先进的临床应用和农村地区不均衡的可及性相结合，使得医疗系统购买者必须投资高效、长效的药物，并为更广大人群提供便捷的零售和线上销售管道。健康计画和公共卫生计画决定了采购的优先顺序，而远端医疗的扩展则持续改变处方的处方笺和配送方式。

欧洲、中东和非洲的监管和文化多样性要求企业制定细緻的打入市场策略。一些欧洲法规结构强调严格的临床证据和上市后监测，而一些中东和北非国家则优先考虑本地生产奖励和公共部门分销。这些因素会影响临床试验设计、产品标籤和合作模式的决策。在许多市场中，人们对避孕的文化态度以及当地医务人员的作用会影响避孕方法的采用模式，尤其是对于非荷尔蒙和草药替代品。

亚太地区涵盖频谱广泛，既有高度工业化的供应基地，也有传统医药使用率高、消费者偏好独特的市场。虽然亚太地区的一些製造能力支持全球材料和成品供应链，但当地的监管要求和报销惯例差异很大。在某些地区，传统草药形成了平行的需求管道，企业必须理解并尊重这些管道。整体而言，每个地区的策略都必须在集中生产效率与当地监管合规性以及符合当地文化的商业性模式之间取得平衡，以确保药品的可及性和接受度。

竞争情报和企业策略揭示了创新、供应链弹性和数位服务如何重塑避孕药研发领域的领导地位

竞争动态青睐那些将差异化临床资产与韧性供应链和卓越患者服务相结合的公司。主要企业正在投资下一代荷尔蒙和非荷尔蒙产品，加速长效製剂的开发，并探索针对男性的药物，以扩大潜在市场。开发商、契约製造和分销合作伙伴之间的策略联盟日益普遍，这不仅能够加快规模扩张，拓宽通路覆盖范围，还能降低资本强度。

其他公司则透过材料创新和使用者体验重塑来实现差异化，优化质地、包装和说明书，以提高接受度和依从性。远端医疗整合、依从性支援工具以及网路药局合作等数位化能力正在成为推动客户获取和保留的核心竞争优势。同时，拥有强大监管能力和多元化製造地的公司更有能力吸收政策和关税带来的衝击。对于寻求收购目标或合作以填补产品组合空白的现有企业而言，将临床新颖性与敏捷商业化模式相结合的新参与企业既是挑战，也是机会。总体而言，竞争格局正在从纯粹以产品为中心的竞争转向生态系统竞争，其中服务、供应链可靠性和监管敏捷性与临床差异化同等重要。

高阶主管应采取哪些战术性和策略行动来加强采购、加速材料创新、扩大数位覆盖范围，并使其产品组合与细分用户需求保持一致

产业领导者应优先考虑几项协同行动，以确保短期稳定和长期成长。首先，多元化供应商基础并制定紧急采购计划，将减少贸易中断和关税波动带来的风险。其次，加速非乳胶材料的开发和商业化，将解决过敏问题，提升市场吸引力，同时降低单一材料类别集中的风险。第三，拓展数位管道和远端医疗伙伴关係关係，将利用不断变化的购买行为，并透过整合支援工具提高依从性。

同时，企业应根据上述特定细分市场自订产品系列和通讯，将临床属性与最终用户需求（例如青少年教育、成人便利性和停经后安全考量）结合。积极与监管机构和付款方沟通，明确证据要求和报销途径，可以促进产品进入市场并减少上市不确定性。最后，将永续性和道德采购纳入采购和生产决策，将维护品牌声誉并满足相关人员日益增长的期望。这些行动共同构成了领导者在创新、营运韧性和以客户为中心的商业化之间寻求平衡的可行蓝图。

透过结合相关人员访谈、文献综合、供应链映射和情境分析的严格混合方法研究途径检验了见解

支撑本分析的研究结合了定性和定量方法，以确保研究的稳健性和实际意义。主要研究包括对临床医生、采购负责人、监管专家和分销主管的结构化访谈，以收集关于临床应用、采购挑战和管道动态的第一手观点。二级资讯来源包括同侪审查的临床文献、监管备案文件、产品标籤和公开的政策文件，以检验临床和安全相关的声明。此外，供应链分析绘製了物料流和製造足迹，以评估贸易政策变化对产品的影响。

分析方法包括跨细分市场综合分析（用于将产品属性与最终用户需求结合）和情境分析（用于检验政策变化和供应链中断的影响）。研究结果与资料来源和专家评审相结合，以最大程度地减少偏差并提高可靠性。调查方法的局限性包括区域层面数据品质参差不齐以及监管指南的不断演变，需要定期更新以保持有效性。出于伦理方面的考虑，我们在讨论传统和草药避孕方法时，与临床专家沟通并尊重文化背景。这些综合方法为本报告中提出的见解和建议提供了一个合理的框架。

整体结论将不断发展的技术、监管和供应链动态转化为相关人员的现实策略重点

总而言之，在技术进步、分销管道演变、材料创新以及影响临床和消费行为的政策动态的推动下，避孕领域正在经历意义深远的变化。有效的策略应将临床差异化与营运韧性结合，实现供应商多元化，在适当情况下采用非乳胶材料，并整合数位化服务，以满足使用者的需求。区域差异和层层细分需要量身定制的方法，既要利用全球製造的优势，也要尊重当地法规和文化背景。

相关人员若能果断采取行动，产品系列与明确的最终用户需求保持一致，同时提高供应链透明度和监管参与度，将最有可能获得长期价值。本文提供的见解和建议旨在帮助企业主管、临床负责人和商业团队化复杂为机会，并做出决策，从而改善可及性、提升用户体验，并在快速变化的环境中持续创新。

目录

第一章 引言

第二章分析方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

第五章 市场洞察

  • 安全性问题导致对非荷尔蒙避孕方法的需求增加
  • 男性避孕措施的采用率不断提高及其对市场动态的影响
  • 数位健康应用程式和穿戴式装置整合可追踪避孕药具的使用情况
  • 扩大远端医疗服务，改善避孕咨询服务的可近性
  • 增加对长效可逆避孕药的投资以满足患者偏好

第六章：美国关税的累积影响（2025年）

第七章：人工智慧（AI）的累积影响（2025年）

第八章 避孕药具市场（按类型）

  • 事后紧急避孕药
    • 子宫内避孕器（IUD）
    • 口服避孕药
  • 荷尔蒙
    • 植入式避孕器
    • 注射避孕药
    • 口服避孕药
    • 经皮避孕药
  • 非荷尔蒙
    • 屏障法
    • 草药避孕药
      • 阿育吠陀
      • 同类疗法
    • 自然疗法
  • 永恆的
    • 输卵管结扎
    • 切除术

第九章 避孕药市场（按剂型）

  • 修补
  • 丸
    • 单相
    • 多态性
  • 戒指

第十章 避孕药市场（依作用机转）

  • 预防植入
  • 杀精作用
  • 抑制排卵

第11章 避孕药市场（依材料类型）

  • 乳胶基底
  • 不含乳胶
    • 腈纶
    • 聚异戊二烯
    • 聚氨酯

第十二章 避孕药具市场（依使用时长）

  • 长期
  • 短期

第十三章 避孕药具市场（依使用频率）

  • 酌情使用
  • 一直在使用

第十四章 避孕药具市场销售管道

  • 离线
    • 医院药房
    • 药局
  • 在线的
    • 电商平台
    • 网路药局

第 15 章避孕药市场（依应用）

  • 一般用途
  • 性交后使用

第十六章 避孕药具市场（依最终用户）

  • 女士
    • 青春期
    • 成人
    • 停经后
  • 男性

第十七章 避孕药具市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十八章 避孕药具市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十九章 各国避孕药具市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第二十章 竞争格局

  • 市占率分析（2024年）
  • FPNV定位矩阵（2024年）
  • 竞争分析
    • Abbvie Inc.
    • Bayer AG
    • Cipla Limited
    • Johnson & Johnson Services, Inc.
    • Lupin Limited
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
Product Code: MRR-4316E4E895C4

The Contraceptive Market is projected to grow by USD 69.02 billion at a CAGR of 7.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 38.40 billion
Estimated Year [2025] USD 41.13 billion
Forecast Year [2032] USD 69.02 billion
CAGR (%) 7.60%

A strategic orientation to the modern contraceptive environment highlighting innovation, access, regulatory nuance, and user-centric priorities

The contraceptive landscape stands at an inflection point where clinical innovation, shifting consumer expectations, and evolving policy environments converge to reshape product development and access. Advances in biomedical technologies and formulation science are expanding the range of options available to end-users, while digital health platforms and telemedicine are changing how contraception is discovered, prescribed, and obtained. At the same time, societal conversations around reproductive autonomy and inclusivity are influencing both demand patterns and the regulatory scrutiny that products face. These dynamics require stakeholders across the value chain to consider not only efficacy and safety, but also user experience, acceptability, and equity of access.

Transitioning from legacy product portfolios to a future-ready mix requires a deep understanding of clinical differentiation and end-user segmentation. Health systems and payers are emphasizing long-term outcomes and cost-effective care pathways, which in turn affects procurement strategies and formulary decisions. Simultaneously, manufacturers and innovators must navigate complex supply chains, regulatory compliance, and sustainability considerations while accelerating next-generation product development. The combination of these forces creates both significant opportunities for targeted innovation and acute operational risks for organizations that are slow to adapt. Accordingly, this introduction frames the broader patterns that inform the remainder of the analysis and sets the stage for practical recommendations that align scientific progress with real-world access and commercial viability.

Key systemic shifts in technology, distribution, materials, and regulatory practice that are redefining contraceptive choice and delivery models

Over the last decade, several transformative shifts have redefined the contraceptive landscape, driven by converging advances in technology, consumer behavior, and health system priorities. Long-acting reversible contraception has become more prominent in clinical guidelines and practice, prompting manufacturers to emphasize durability, ease of insertion, and minimized side effects. Concurrently, progress in hormonal and non-hormonal formulations-spanning implantables, injectables, oral systems, transdermal patches, and barrier methods-has broadened therapeutic choices, enabling more personalized care pathways.

Digital and distribution innovations have accelerated change by lowering friction for prescription access and adherence support. Telehealth consultations combined with e-commerce and online pharmacy fulfillment are altering the balance between traditional clinical settings and consumer-facing channels. At the same time, material science improvements, including alternatives to conventional latex products, are creating opportunities to address allergy concerns and enhance user comfort. Regulatory landscapes have adjusted to accommodate these innovations, yet also introduce complexity around clinical endpoints, post-market surveillance, and cross-border distribution. Taken together, these shifts are not incremental; they change how products are developed, marketed, and delivered, forcing stakeholders to rethink clinical engagement, patient education, and supply chain resilience in an increasingly interconnected ecosystem.

Assessing how tariff measures in major markets have reshaped sourcing, materials choices, inventory planning, and access dynamics across contraceptive supply chains

The introduction of tariff measures by a major economy in 2025 created immediate reverberations across global supply chains for contraceptive products and their constituent materials. Manufacturers sourcing raw materials or components from affected jurisdictions faced higher landed costs, prompting rapid reassessment of procurement strategies and supplier diversification. In many cases, contract manufacturers and finished-goods producers began evaluating nearshoring options, dual-sourcing arrangements, and stockpiling approaches to mitigate disruption, which in turn affected lead times and inventory models for hospitals, pharmacies, and e-commerce distributors.

Beyond procurement, tariff-related cost pressures influenced strategic decisions concerning product formulation and material selection. For example, supply chain sensitivities accelerated interest in non-latex alternatives such as nitrile, polyisoprene, and polyurethane for barrier products, as firms sought materials with more robust multi-region supply bases. Regulatory compliance costs and customs delays also introduced friction for time-sensitive product launches and for emergency contraceptives that require rapid distribution channels. Clinicians and health systems experienced operational strain when procurement timelines shifted, while payers and purchasing groups began scrutinizing total cost implications, including the downstream effects on patient access. The aggregate effect has been to heighten the importance of supply chain transparency, contractual flexibility, and strategic sourcing as core competencies for companies operating in the contraceptive arena.

Granular segmentation insights that connect product types, formulations, modes of action, materials, and end-user profiles to actionable development and commercial strategies

Segment-level differentiation offers a pragmatic framework for prioritizing product development and commercial strategies. By Type, the market encompasses emergency contraceptives divided into intrauterine devices and pills, hormonal methods including implantable, injectable, oral and transdermal options, non-hormonal approaches featuring barrier methods as well as herbal choices split into Ayurvedic and homeopathic traditions and natural methods, and permanent solutions such as tubal ligation and vasectomy. These distinctions reveal divergent clinical pathways: long-acting and permanent options tend to engage specialist care and health-system procurement, whereas pills, patches, and barrier methods often interact with broader primary care and retail channels.

Considering Formulation, patch, pill and ring formats carry different adherence and acceptability profiles; within pills, the distinction between monophasic and multiphasic regimens informs counseling and side-effect management. Mode of Action segmentation-preventing implantation, spermicidal action, and suppression of ovulation-connects directly to clinical outcomes and patient education priorities, shaping labeling and safety monitoring. Material Type splits into latex-based and non-latex offerings, with the latter subdivided into nitrile, polyisoprene, and polyurethane, each presenting trade-offs in cost, tactile properties, and allergenicity.

Duration and Usage Frequency segmentation-long-term versus short-term and on-demand versus regular use-highlight pathways for engagement and adherence interventions, while Sales Channel distinctions between offline outlets such as hospital pharmacies and retail pharmacies and online channels including e-commerce platforms and online pharmacies underscore shifting acquisition behaviors. Application differentiates general use from post-coital use, signaling differing urgency and distribution requirements. End-User segmentation recognizes female and male cohorts, with further granularity for females across adolescent, adult, and post-menopausal groups, which affects clinical guidance, marketing tone, and packaging. Together, these segmentation lenses provide a cohesive map for aligning product features, regulatory strategy, and go-to-market execution to specific clinical and consumer needs.

Regional strategic imperatives describing how regulatory diversity, cultural norms, manufacturing hubs, and access models shape contraceptive deployment across global markets

Regional dynamics exert a substantial influence on product adoption, regulatory pathways, and distribution models. In the Americas, a mix of advanced clinical adoption in urban centers and uneven access across rural communities creates a dual imperative: invest in both high-efficacy long-acting options for health-system purchasers and accessible retail and online offerings for broader populations. Payer systems and public health programs shape procurement priorities, and telemedicine expansion continues to alter how prescriptions are issued and fulfilled.

Across Europe, Middle East & Africa, regulatory heterogeneity and cultural diversity require nuanced market entry strategies. Regulatory frameworks in parts of Europe emphasize rigorous clinical evidence and post-market surveillance, while certain countries in the Middle East and Africa prioritize local manufacturing incentives and public-sector distribution. These conditions influence decisions around clinical trial design, labeling, and partnership models. In many markets, cultural attitudes toward contraception and the role of community health workers affect adoption patterns, especially for non-hormonal and herbal alternatives.

The Asia-Pacific region presents a broad spectrum from highly industrialized supply hubs to markets with strong traditional medicine use and distinct consumer preferences. Manufacturing capacity in parts of Asia-Pacific supports global supply chains for materials and finished goods, yet local regulatory expectations and reimbursement practices vary substantially. Traditional herbal practices in some locales create parallel demand channels that companies must understand and engage with respectfully. Overall, regional strategies must balance centralized manufacturing efficiencies with local regulatory compliance and culturally informed commercial approaches to ensure both access and acceptance.

Competitive intelligence and corporate strategies revealing how innovation, supply chain resilience, and digital services are reshaping leadership in contraceptive development

Competitive dynamics favor organizations that combine differentiated clinical assets with resilient supply chains and compelling patient-facing services. Leading companies are investing in next-generation hormonal and non-hormonal formulations, accelerating work on long-acting modalities, and exploring male-targeted agents to broaden addressable markets. Strategic alliances between developers, contract manufacturers, and distribution partners are increasingly common, enabling faster scale-up and broader channel reach while mitigating capital intensity.

Other firms are differentiating through material innovation and user experience redesign, optimizing tactile properties, packaging, and instructions for use to improve acceptability and adherence. Digital capabilities, including telehealth integrations, adherence support tools, and e-pharmacy partnerships, are becoming core competitive levers that drive customer acquisition and retention. At the same time, companies with strong regulatory affairs capabilities and diverse manufacturing footprints are better positioned to absorb policy and tariff-driven shocks. Emerging entrants that combine clinical novelty with agile commercialization models present both competition and opportunity for incumbents seeking acquisition targets or partnerships to fill portfolio gaps. Overall, the competitive landscape is shifting from purely product-centric competition to ecosystem competition where service, supply chain reliability, and regulatory agility matter as much as clinical differentiation.

Tactical and strategic actions for executives to strengthen sourcing, accelerate material innovation, expand digital reach, and align portfolios with segmented user needs

Industry leaders should prioritize several coordinated actions to secure both short-term stability and long-term growth. First, diversifying the supplier base and developing contingency sourcing plans will reduce exposure to trade disruptions and tariff volatility; investing in dual-sourcing and qualified regional suppliers enhances operational flexibility. Second, accelerating development and commercialization of non-latex materials will address allergy concerns and broaden market appeal, while simultaneously reducing concentration risk tied to single material classes. Third, expanding digital channels and telehealth partnerships will capture shifting acquisition behavior and improve adherence through integrated support tools.

In parallel, companies should tailor product portfolios and messaging to specific segments identified earlier, aligning clinical attributes with end-user needs such as adolescent education, adult convenience, or post-menopausal safety considerations. Engaging proactively with regulators and payers to clarify evidence requirements and reimbursement pathways will smooth market entry and reduce launch uncertainty. Finally, embedding sustainability and ethical sourcing into procurement and manufacturing decisions will protect brand reputation and respond to growing stakeholder expectations. These actions, taken together, form a pragmatic roadmap for leaders seeking to balance innovation with operational resilience and customer-centric commercialization.

A rigorous mixed-methods research approach combining stakeholder interviews, literature synthesis, supply chain mapping, and scenario analysis to validate insights

The research underpinning this analysis combined qualitative and quantitative approaches to ensure robustness and practical relevance. Primary research included structured interviews with clinicians, procurement officers, regulatory specialists, and distribution executives to capture first-hand perspectives on clinical adoption, sourcing challenges, and channel dynamics. Secondary sources comprised peer-reviewed clinical literature, regulatory filings, product labels, and publicly available policy documents to validate clinical and safety-related assertions. In addition, supply chain analyses mapped material flows and manufacturing footprints to assess vulnerability to trade policy shifts.

Analytical methods included cross-segmentation synthesis to align product attributes with end-user needs and scenario analysis to examine the implications of policy changes and supply-chain disruptions. Findings were triangulated across data sources and expert review to minimize bias and enhance credibility. Limitations of the methodology include variability in region-level data quality and the evolving nature of regulatory guidance, which necessitate periodic updates to maintain relevance. Ethical considerations guided the engagement with clinical experts and respect for cultural contexts when discussing traditional and herbal contraceptive practices. Together, these methods produced a defensible framework for the insights and recommendations presented in this report.

Summative conclusions that translate the evolving technological, regulatory, and supply chain dynamics into pragmatic strategic priorities for stakeholders

In closing, the contraceptive landscape is undergoing meaningful transformation driven by technological progress, evolving distribution channels, materials innovation, and policy dynamics that together influence clinical practice and consumer behavior. Effective strategies will combine clinical differentiation with operational resilience-diversifying suppliers, embracing non-latex materials where appropriate, and integrating digital services to meet users where they seek care. Regional nuances and segmentation layers call for tailored approaches that respect local regulatory and cultural contexts while leveraging global manufacturing strengths.

Stakeholders that act decisively to align product portfolios with clearly defined end-user needs, while strengthening supply chain transparency and regulatory engagement, will be best positioned to capture long-term value. The insights and recommendations offered here are designed to help executives, clinical leaders, and commercial teams convert complexity into opportunity, supporting decisions that improve access, enhance user experience, and sustain innovation in a rapidly changing environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing demand for non-hormonal contraceptive methods driven by safety concerns
  • 5.2. Rising adoption of male contraceptive options and implications for market dynamics
  • 5.3. Integration of digital health apps and wearable devices to track contraceptive usage
  • 5.4. Expansion of telehealth services improving access to contraceptive counseling and delivery
  • 5.5. Increased investment in long-acting reversible contraceptives to meet patient preferences

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Contraceptive Market, by Type

  • 8.1. Emergency Contraceptives
    • 8.1.1. IUDs
    • 8.1.2. Pills
  • 8.2. Hormonal
    • 8.2.1. Implantable Contraceptives
    • 8.2.2. Injectable Contraceptives
    • 8.2.3. Oral Contraceptives
    • 8.2.4. Transdermal Contraceptives
  • 8.3. Non-Hormonal
    • 8.3.1. Barrier Methods
    • 8.3.2. Herbal Contraceptives
      • 8.3.2.1. Ayurvedic
      • 8.3.2.2. Homeopathic
    • 8.3.3. Natural Methods
  • 8.4. Permanent
    • 8.4.1. Tubal Ligation
    • 8.4.2. Vasectomy

9. Contraceptive Market, by Formulation

  • 9.1. Patch
  • 9.2. Pill
    • 9.2.1. Monophasic
    • 9.2.2. Multiphasic
  • 9.3. Ring

10. Contraceptive Market, by Mode Of Action

  • 10.1. Prevent Implantation
  • 10.2. Spermicidal Action
  • 10.3. Suppress Ovulation

11. Contraceptive Market, by Material Type

  • 11.1. Latex-Based
  • 11.2. Non-Latex
    • 11.2.1. Nitrile
    • 11.2.2. Polyisoprene
    • 11.2.3. Polyurethane

12. Contraceptive Market, by Duration

  • 12.1. Long-Term
  • 12.2. Short-Term

13. Contraceptive Market, by Usage Frequency

  • 13.1. On-Demand
  • 13.2. Regular Use

14. Contraceptive Market, by Sales Channel

  • 14.1. Offline
    • 14.1.1. Hospital Pharmacy
    • 14.1.2. Pharmacy
  • 14.2. Online
    • 14.2.1. E-Commerce Platforms
    • 14.2.2. Online Pharmacy

15. Contraceptive Market, by Application

  • 15.1. General Use
  • 15.2. Post-Coital Use

16. Contraceptive Market, by End-User

  • 16.1. Female
    • 16.1.1. Adolescent
    • 16.1.2. Adult
    • 16.1.3. Post-Menopausal
  • 16.2. Male

17. Contraceptive Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Contraceptive Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Contraceptive Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. Competitive Landscape

  • 20.1. Market Share Analysis, 2024
  • 20.2. FPNV Positioning Matrix, 2024
  • 20.3. Competitive Analysis
    • 20.3.1. Abbvie Inc.
    • 20.3.2. Bayer AG
    • 20.3.3. Cipla Limited
    • 20.3.4. Johnson & Johnson Services, Inc.
    • 20.3.5. Lupin Limited
    • 20.3.6. Merck & Co., Inc.
    • 20.3.7. Pfizer Inc.
    • 20.3.8. Sanofi S.A.
    • 20.3.9. Teva Pharmaceutical Industries Ltd.
    • 20.3.10. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 19. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AMERICAS CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. EUROPE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. AFRICA CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. ASEAN CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. GCC CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. EUROPEAN UNION CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. BRICS CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. G7 CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. NATO CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 36. GLOBAL CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 37. CONTRACEPTIVE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 38. CONTRACEPTIVE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CONTRACEPTIVE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CONTRACEPTIVE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CONTRACEPTIVE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 321. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 322. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 327. AMERICAS CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 328. AMERICAS CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 329. AMERICAS CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. AMERICAS CONTRACEPTIVE MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. AMERICAS CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 332. AMERICAS CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 333. AMERICAS CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 334. AMERICAS CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 335. AMERICAS CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 336. AMERICAS CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 337. AMERICAS CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 338. AMERICAS CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 339. AMERICAS CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2024 (USD MILLION)
  • TABLE 340. AMERICAS CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2025-2032 (USD MILLION)
  • TABLE 341. AMERICAS CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 342. AMERICAS CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 343. AMERICAS CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2024 (USD MILLION)
  • TABLE 344. AMERICAS CONTRACEPTIVE MARKET SIZE, BY PILL, 2025-2032 (USD MILLION)
  • TABLE 345. AMERICAS CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 346. AMERICAS CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 347. AMERICAS CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)

TABLE 3